Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction

References

• Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007;4(4):214-25
   PubMedGoogle Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014;129(3):399-410
   PubMed Web of Science ®Google Scholar
• Stone NJ, Lichtenstein AH, Bairey Merz CN, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45
   PubMed Web of Science ®Google Scholar
• Matthew K, Ito P, Bays H, et al. NLA recommendations for patient-centered management of dyslipidemia. J Clin Lipidol 2014; In press
   Google Scholar
• Hunt KJ, Resendez RG, Williams K, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110(10):1251-7
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: transcriptional mediators of lipid homeostasis. Cold Spring Harb Symp Quant Biol 2002;67:491-8
   PubMedGoogle Scholar
• Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol 2012;159(3):169-76
   PubMed Web of Science ®Google Scholar
• Bays H, Cohen DE, Chalasani N, Harrison SA. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014;8(3 Suppl):S47-57
   PubMed Web of Science ®Google Scholar
• Brault M, Ray J, Gomez YH, et al. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014;63(6):735-45
   PubMed Web of Science ®Google Scholar
• Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004;279(47):48865-75
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354(12):1264-72
   PubMed Web of Science ®Google Scholar
• Saavedra YG, Day R Fau - Seidah NG, Seidah NG. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem 2012;287(52):43492-501
   Google Scholar
• Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007;14(5):413-19
   PubMed Web of Science ®Google Scholar
• Hampton EN, Knuth MW, Li J, et al. The self-inhibited structure of full-length. PCSK9 at 1.9. A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci USA 2007;104(37):14604-9
   PubMed Web of Science ®Google Scholar
• Piper DE, Jackson S, Liu Q, et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 2007;15(5):545-52
   Google Scholar
• McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007;282(29):20799-803
   PubMed Web of Science ®Google Scholar
• Li J, Tumanut C, Gavigan JA, et al. Secreted PCSK9 promotes. LDL receptor degradation independently of proteolytic activity. Biochem J 2007;406(2):203-7
   PubMedGoogle Scholar
• Betzel C, Gourinath S, Kumar P, et al. Structure of a serine protease proteinase K from Tritirachium album limber at 0.98 A resolution. Biochemistry 2001;40(10):3080-8
   PubMed Web of Science ®Google Scholar
• Wright CS, Alden RA, Kraut J. Structure of subtilisin BPN’ at 2.5 angstrom resolution. Nature 1969;221(5177):235-42
   Google Scholar
• McPhalen CA, James MN. Structural comparison of two serine proteinase-protein inhibitor complexes: eglin-c-subtilisin Carlsberg and CI-2-subtilisin Novo. Biochemistry 1988;27(17):6582-98
   Google Scholar
• Henrich S, Cameron A, Bourenkov GP, et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 2003;10(7):520-6
   PubMedGoogle Scholar
• Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282(25):18602-12
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Lagace TA, McNutt MC, et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 2008;105(6):1820-5
   PubMed Web of Science ®Google Scholar
• Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37(2):161-5
   PubMed Web of Science ®Google Scholar
• Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006;78(3):410-22
   PubMed Web of Science ®Google Scholar
• Fokkema IF, den Dunnen JT, Taschner PE. LOVD: easy creation of a locus-specific sequence variation database using an “LSDB-in-a-box” approach. Hum mut 2005;26(2):63-8
   Google Scholar
• Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 2012;11(5):367-83
   PubMed Web of Science ®Google Scholar
• Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003;100(3):928-33
   PubMed Web of Science ®Google Scholar
• Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res 2008;49(6):1303-11
   PubMed Web of Science ®Google Scholar
• Postmus I, Trompet S, de Craen AJ, et al. PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J Lipid Res 2013;54(2):561-6
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009;94(7):2537-43
   PubMed Web of Science ®Google Scholar
• Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin chem 2008;54(6):1038-45
   Google Scholar
• Mayne J, Raymond A, Chaplin A, et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 2007;361(2):451-6
   Google Scholar
• Fan D, Yancey PG, Qiu S, et al. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry 2008;47(6):1631-9
   PubMed Web of Science ®Google Scholar
• Kosenko T, Golder M, Leblond G, et al. Low-density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated LDL receptor degradation. J Biol Chem 2013;288(12):8279-88
   PubMed Web of Science ®Google Scholar
• Sun H, Samarghandi A, Zhang N, et al. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 2012;32(7):1585-95
   PubMed Web of Science ®Google Scholar
• Tavori H, Fan D, Blakemore JL, et al. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 2013;127(24):2403-13
   PubMed Web of Science ®Google Scholar
• Tavori H, Giunzioni I, Linton MF, Fazio S. Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis. Circ Res 2013;113(12):1290-5
   PubMed Web of Science ®Google Scholar
• Raal F, Panz V, Immelman A, Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2013;2(2):e000028
   Web of Science ®Google Scholar
• Gao F, Ihn HE, Medina MW, Krauss RM. A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function. Hum Mol Genet 2012;22(7):1424-31
   Google Scholar
• Ason B, Tep S, Davis HR Jr, et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J lipid Res 2011;52(4):679-87
   Google Scholar
• Rashid S, Tavori H, Brown P, et al. PCSK9 promotes intestinal overproductin of triglyceride-rich apolipoprotien-b liporptoein throug both ldl-receptor dependent and independent mechanisms. Circulation 2014;130(4):431-41
   Google Scholar
• Benjannet S, Rhainds D, Hamelin J, et al. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006;281(41):30561-72
   PubMed Web of Science ®Google Scholar
• Lipari MT, Li W, Moran P, et al. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem 2012;287(52):43482-91
   PubMed Web of Science ®Google Scholar
• Han B, Eacho PI, Knierman MD, et al. Isolation and Characterization of the Circulating Truncated Form of PCSK9. J lipid Res 2014;55(7):1505-14
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89(3):331-40
   PubMed Web of Science ®Google Scholar
• Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008;283(4):2363-72
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J lipid Res 2007;48(4):763-7
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014;383(9911):60-8
   PubMed Web of Science ®Google Scholar
• REGENERON. Sanofi and regeneron report positive top-line results with alirocumab from first phase 3 study of a PCSK9 inhibitor for LDL cholesterol reduction - alirocumab monotherapy reduced "bad" cholesterol three times more than ezetimibe. 2013
   Google Scholar
• Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128(19):2113-20
   PubMed Web of Science ®Google Scholar
• Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N.Engl J Med 2012;367(20):1891-900
   PubMed Web of Science ®Google Scholar
• Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366(12):1108-18
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59(25):2344-53
   Google Scholar
• Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atheroscler 2013;228(1):18-28
   PubMed Web of Science ®Google Scholar
• Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144(6):1169-76
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010;9(4):325-38
   PubMed Web of Science ®Google Scholar
• Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50(Suppl):S172-7
   PubMed Web of Science ®Google Scholar
• Chan DC, Lambert G, Barrett PH, et al. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? Clin chem 2009;55(11):2049-52
   PubMed Web of Science ®Google Scholar
• Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380(9836):29-36
   PubMed Web of Science ®Google Scholar
• Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atheroscler 2007;193(2):445-8
   PubMed Web of Science ®Google Scholar
• Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008;49(2):394-8
   PubMed Web of Science ®Google Scholar
• Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J of Lipid Res 2010;51(9):2714-21
   PubMed Web of Science ®Google Scholar
• Stein EA, Raal F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 2014;65:417-31
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84(5):548-58
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the odyssey fh studies. Cardiovasc Drugs Ther 2014;28(3):281-9
   PubMed Web of Science ®Google Scholar
• Therapeutic monoclonal antibodies approved or in review in the European Union or United States. The Antibody Society. 2014
   Google Scholar
• Reichert JM. Antibodies to watch in 2014: mid-year update. MAbs 2014;6(4):799-802
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010;9(10):767-74
   PubMed Web of Science ®Google Scholar
• Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008;51(1):8-14
   PubMed Web of Science ®Google Scholar
• Kramer W. Novel drug approaches in development for the treatment of lipid disorders. Exp Clin Endocrinol Diabetes 2013;121(10):567-80
   Google Scholar
• Jones PH. Comparing HMG-CoA reductase inhibitors. Clin Cardiol 2003;26(1 Suppl):I15-20
   Google Scholar
• Sheridan C. Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol 2013;31(12):1057-8
   Google Scholar
• Drewe E, Powell RJ. Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002;55(2):81-5
   PubMed Web of Science ®Google Scholar